The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.
May 17th 2024
The FDA has approved tarlatamab, a novel bispecific T-cell engager, to treat patients with extensive-cell small cell lung cancer (SCLC).
December 14th 2023
Managing ILD Treatment: Utilization Tools vs Self-Regulation
July 6th 2022Kristin Highland, MD, and Ryan Haumschild, PharmD, MS, MBA, compare management tools to self-regulation for the best ILD treatment outcome, as well as patient access to nintedanib, pirfenidone, and tocilizumab through special pharmacies.
Watch